Show simple item record

dc.contributor.authorBatwala, Vincent
dc.contributor.authorMagnussen, Pascal
dc.contributor.authorNuwaha, Fred
dc.date.accessioned2020-02-07T07:05:50Z
dc.date.available2020-02-07T07:05:50Z
dc.date.issued2010
dc.identifier.citationBatwala, V., Magnussen, P., & Nuwaha, F. (2010). Challenges to implementation of artemisinin combination therapy policy in Uganda. International health, 2(4), 262-268.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/487
dc.description.abstractUganda launched an artemisinin combination therapy (ACT) policy in 2006, using artemether-lumefantrine (AL) as first-line treatment for uncomplicated malaria, but insufficient information is available regarding its implementation. Semi-structured interviews were conducted with key personnel: 32 clinical and four laboratory staff from 32 health centres (HCs) in Bushenyi and Iganga districts and the Ministry of Health. Structured interviews with 613 patients receiving malaria treatment at six randomly chosen HCs were held. Data were collected on availability of antimalarials, treatment guidelines, staffing and malaria treatment decisions. Posts for clinical staff were inadequately filled. Only 15 (46.9%) HCs stocked AL for all weight categories. Nationwide, AL was out-of-stock March–July 2007. Twenty-one (65.6%) HCs stocked chloroquine. Out of 193 patients, 177 (91.7%) used antimalarials other than AL before coming to HCs. The unrecommended antimalarials were mainly sourced from the private for profit (PFP) sector yet there were no guidelines regarding provision of AL in the PFP sector. Only 53/613 (8.6%) patients were examined for parasites and only 8 (15.1%) had a positive blood slide. The majority of the patients attending HCs (560; 91.4%) received antimalarials but only 323 (57.7%) received AL. In order to improve the implementation of the current policy, AL should be availed in adequate amounts at all points of care including the PFP sector; non-recommended drugs should be withdrawn from the market and it should be ensured that malaria is confirmed by laboratory diagnosis. Study registration: Clinicaltrials.gov NCT00565071.en_US
dc.description.sponsorshipThe study was funded in part with grants from the Department for International Development (DFID) through the TARGETS project of Makerere University School of Public Health; and DBL-Centre for Health Research and Development, Denmark.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectArtemisinin Combination Therapyen_US
dc.subjectMalaria diagnosisen_US
dc.subjectTreatmenten_US
dc.titleChallenges to implementation of artemisinin combination therapy policy in Ugandaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record